AffaMed Therapeutics
Cen Xu has extensive work experience in the pharmaceutical industry. They started their career at Bristol-Myers Squibb Company in 1998 as a Sr. Research Investigator, working there until 2006. In 2006, Cen Xu joined Amgen as an Executive Medical Director and held this role for 15 years until 2021. Currently, they are the Chief Scientific Officer at AffaMed Therapeutics.
Cen Xu obtained a Doctor of Philosophy (PhD) in Pharmacology from Illinois State University in 1996.
This person is not in any offices
AffaMed Therapeutics
AffaMed Therapeutics is a clinical stage therapeutic company focused on developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmic, neurological and psychiatric disorders for patients in Greater China and around the world. The leadership team of AffaMed Therapeutics has gained deep industry expertise and an extensive track record in high-quality discovery, clinical development, regulatory affairs, manufacturing, commercial operations, and business development at leading multi-national pharmaceutical companies in China and globally.